IJPMBS 2024 Vol.13(4): 128-135
doi: 10.18178/ijpmbs.13.4.128-135
doi: 10.18178/ijpmbs.13.4.128-135
Research Progress of Talaromyces Marneffei
Youming Liu
RCF Experimental School, Beijing, China
Email: liuyouming@rdfzcygj.cn
Email: liuyouming@rdfzcygj.cn
Manuscript received August 29, 2024; revised September 28, 2024; accepted October 8, 2024; published December 23, 2024.
Abstract—Talaromyces marneffei has a very high mortality rate and is prone to devastating effects on immunocompromised people, but there is far less attention paid to diseases caused by Talaromyces marneffei are globally. Diseases that caused by Talaromyces marneffei may present with fever, anemia, emaciation, respiratory symptoms, hepatosplenomegaly, lymph node enlargement, and osteolytic destruction. The treatment of Talaromyces marneffei infection is limited, and the commonly used drugs are amphotericin B, itraconazole and voriconazole. In this paper, the biological characteristics, epidemiology, infection and pathogenic mechanism of Talaromyces marneffei were systematically discussed in order to provide theoretical basis for the clinical treatment of Talaromycosis.
Keywords—Talaromyces marneffei, virulence factor, bidirectional fungus, immune system
Keywords—Talaromyces marneffei, virulence factor, bidirectional fungus, immune system
Cite: Youming Liu, "Research Progress of Talaromyces Marneffei," International Journal of Pharma Medicine and Biological Sciences, Vol. 13, No. 4, pp. 128-135, 2024.
Copyright © 2024 by the authors. This is an open access article distributed under the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits use, distribution and reproduction in any medium, provided that the article is properly cited, the use is non-commercial and no modifications or adaptations are made.